<DOC>
	<DOC>NCT01809262</DOC>
	<brief_summary>Primary objective: To investigate bronchodilator effect and safety of single doses of BI 1744 CL inhaled via Respimat inhaler, Secondary objective: to characterize pharmacokinetics of BI 1744 CL. Olodaterol dose 40 mcg was investigated only in the open-label extension part for additional PK assessments which are not defined as primary or secondary endpoints.</brief_summary>
	<brief_title>Single Dose Ranging Study of BI 1744 CL (Olodaterol) in Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Olodaterol</mesh_term>
	<criteria>Inclusion criteria: 1. Diagnosis of chronic obstructive pulmonary disease 2. Smoking history of more than 10pack years Exclusion criteria: 1. History of asthma, allergic rhinitis, myocardial infarction or unstable of lifethreatening cardiac arrhythmias 2. Marked baseline prolongation of QT/QTc interval</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>